Orchestra BioMed Holdings, Inc.
NASDAQ:OBIOBiotechnology
Healthcare
$7.46 +1.16%
+$0.05 today
- Market cap
- $587.14M
- Beta
- 0.50
- P/E (TTM)
- -2.8
- EPS (TTM)
- -$1.42
52W Low $2.20High $5.42
Volume 1.20M
Average 0.22M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$48.96M
FY 2025 · Annual
Investing Cash Flow
-$26.94M
FY 2025 · Annual
Financing Cash Flow
$88.33M
FY 2025 · Annual
+202.8% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (23.01M) | (33.61M) | (49.12M) | (61.02M) | (52.7M) |
| Depreciation & Amortization | 181K | 222K | 287K | 308K | 327K |
| Deferred Income Tax | 288K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 302K | 3.41M | 7.63M | 10.62M | 11.98M |
| Change in Working Capital | 2.6M | (451K) | (3.31M) | (765K) | (10.37M) |
| Accounts Receivables | 47K | 25K | (3K) | 22K | (3K) |
| Inventory | 1K | (208K) | 131K | (28K) | (137K) |
| Accounts Payables | 1.08M | 0 | 145K | 2.97M | 0 |
| Other Working Capital | 1.47M | (268K) | (3.58M) | (3.73M) | (10.23M) |
| Other Non-Cash Items | 217K | 1.14M | (1.61M) | 308K | 1.81M |
| Operating Cash Flow | (19.43M) | (29.29M) | (46.13M) | (50.56M) | (48.96M) |
| Capital Expenditures | (274K) | (591K) | (78K) | (289K) | (489K) |
| Acquisitions (Net) | (13.29M) | 0 | 0 | (602K) | 0 |
| Purchases of Investments | (213K) | (63.53M) | (142.03M) | (72.65M) | (76.31M) |
| Sales of Investments | 13.5M | 0 | 152.8M | 86.63M | 49.86M |
| Other Investing Activities | 13.29M | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 13.02M | (64.12M) | 10.69M | 13.09M | (26.94M) |
| Debt Repayment | (4M) | 3.55M | (10.85M) | 15M | 17.91M |
| Common Stock Issued | 7K | 109.83M | 254K | 15.04M | 71.97M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 7K | (10.13M) | 56.81M | (864K) | (1.55M) |
| Financing Cash Flow | (3.99M) | 103.26M | 46.22M | 29.17M | 88.33M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (10.41M) | 9.85M | 10.78M | (8.3M) | 12.43M |
| Free Cash Flow | (19.7M) | (29.88M) | (46.21M) | (50.85M) | (49.45M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$52.7M
+ D&A$327.0K
+ Stock-Based Comp$12.0M
+ Deferred Tax$0
- Working Capital-$10.4M
+ Other Non-Cash$1.8M
= Operating Cash Flow-$49.0M
- Capex-$489.0K
= Free Cash Flow-$49.5M
Analysis
FY2025 free cash flow is -$49.5M. FCF conversion is 93.8% of net income. Operating cash flow was -$49.0M, with capex of -$489.0K. The largest bridge item is Stock-Based Comp at $12.0M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Nov 12, 2026 | |
| SC 13D/A | SC 13D/A filing | Nov 12, 2026 | |
| 10-Q | Quarterly report | Nov 10, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 9, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 9, 2026 |
Does OBIO generate free cash flow?
Orchestra BioMed Holdings, Inc. (OBIO) generated -$49.45M of free cash flow in fiscal 2025.
How much operating cash flow does OBIO produce?
Operating cash flow was -$48.96M, before capital expenditures of $489,000.00.
Continue the stock analysis
Jump to another research area for this company.